Fiscal year 2023 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses SILK in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named SILK in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Chas McKhann | $105,871 | $100,000 | $13,123,059 | $0 | $93,275 | $0 | $1,629 | $13,423,834 |
| Chief Executive Officer | ||||||||
| Erica Rogers | 628,672 | 0 | 5,339,332 | 1,515,898 | 559,650 | 0 | 116,352 | 8,159,904 |
| Former President and Chief Executive Officer | ||||||||
| Lucas Buchanan | 506,500 | 0 | 5,788,073 | 0 | 307,377 | 0 | 22,993 | 6,624,943 |
| Chief Operating Officer and Chief Financial Officer | ||||||||
| Andrew Davis | 476,667 | 400,000 | 3,670,932 | 0 | 289,296 | 0 | 29,745 | 4,866,640 |
| Chief Commercial Officer | ||||||||
| Kevin Klemz | 430,000 | 0 | 2,970,296 | 0 | 222,139 | 0 | 13,200 | 3,635,635 |
| Executive Vice President, Chief Legal Officer and Secretary | ||||||||
| Richard Ruedy | 345,833 | 0 | 1,489,026 | 0 | 120,541 | 0 | 9,900 | 1,965,300 |
| Executive Vice President of Regulatory and Clinical Affairs and Quality Assurance | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Chas McKhann | $13,423,834 | — | — | — |
| Erica Rogers | 8,159,904 | 15,277,073 | 3,315,913 | −7,117,169 |
| Lucas Buchanan | 6,624,943 | 9,559,068 | 2,002,733 | −2,934,125 |
| Andrew Davis | 4,866,640 | 7,897,922 | 3,989,680 | −3,031,282 |
| Kevin Klemz | 3,635,635 | 2,376,507 | — | +1,259,128 |
| Richard Ruedy | 1,965,300 | 1,501,138 | 912,704 | +464,162 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Chas McKhann | PSU | 2023-11-02 | 153,020 | 612,083 | 612,083 | 1,224,166 | $8,055,012 |
| Lucas Buchanan | PSU | 2023-03-02 | 2,827 | 11,308 | 11,308 | 22,616 | 784,775 |
| Andrew Davis | PSU | 2023-03-02 | 2,261 | 9,046 | 9,046 | 18,092 | 627,792 |
| Andrew Davis | RSU | 2023-09-15 | — | — | 121,519 | — | 2,056,101 |
| Lucas Buchanan | RSU | 2023-09-15 | — | — | 121,519 | — | 2,056,101 |
| Lucas Buchanan | RSU | 2023-09-15 | — | — | 101,266 | — | 1,713,421 |
| Erica Rogers | PSU | 2023-03-02 | 10,130 | 40,520 | 40,520 | 81,040 | 2,812,088 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Chas McKhann | $0 | $8,055,012 | $0 | 100.0% |
| Lucas Buchanan | 3,769,522 | 784,775 | 0 | 17.2% |
| Andrew Davis | 2,056,101 | 627,792 | 0 | 23.4% |
| Erica Rogers | 0 | 2,812,088 | 0 | 100.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Lucas Buchanan | PSU | 17,289 | — | $212,136 |
| Lucas Buchanan | RSU | 26,925 | — | 330,370 |
| Lucas Buchanan | RSU | 101,266 | — | 1,242,534 |
| Chas McKhann | RSU | 612,083 | — | 7,510,258 |
| Chas McKhann | PSU | 153,020 | — | 1,877,555 |
| Lucas Buchanan | RSU | 121,519 | — | 1,491,038 |
| Andrew Davis | RSU | 121,519 | — | 1,491,038 |
| Kevin Klemz | RSU | 86,076 | — | 1,056,153 |
| Richard Ruedy | RSU | 28,354 | — | 347,904 |
| Lucas Buchanan | RSU | 26,682 | — | 327,388 |
| Andrew Davis | PSU | 17,289 | — | 212,136 |
| Andrew Davis | RSU | 26,115 | — | 320,431 |
| Lucas Buchanan | RSU | 22,035 | — | 270,369 |
| Andrew Davis | RSU | 21,346 | — | 261,915 |
| Kevin Klemz | RSU | 20,011 | — | 245,535 |
| Kevin Klemz | RSU | 15,244 | — | 187,044 |
| Richard Ruedy | RSU | 13,463 | — | 165,191 |
| Richard Ruedy | RSU | 13,341 | — | 163,694 |
| Andrew Davis | RSU | 5,650 | — | 69,326 |
| Lucas Buchanan | RSU | 5,374 | — | 65,939 |
| Lucas Buchanan | RSU | 5,650 | — | 49,326 |
| Lucas Buchanan | PSU | 2,827 | — | 34,687 |
| Andrew Davis | PSU | 2,261 | — | 27,742 |
| Richard Ruedy | RSU | 2,150 | — | 26,381 |
| Kevin Klemz | PSU | 2,120 | — | 26,012 |
| Richard Ruedy | PSU | 1,413 | — | 17,338 |
| Lucas Buchanan | RSU | 1,169 | — | 14,344 |
| Andrew Davis | RSU | 1,169 | — | 14,344 |
| Richard Ruedy | RSU | 838 | — | 10,282 |
| Andrew Davis | Option | 890 | 52.07 | — |
| Andrew Davis | RSU | 225 | — | 2,761 |
| Erica Rogers | Option | 5,747 | 30.93 | — |
| Erica Rogers | Option | 14,407 | 55.3 | — |
| Erica Rogers | Option | 47,993 | 36.01 | — |
| Erica Rogers | Option | 91,519 | 36.01 | — |
| Lucas Buchanan | Option | 2,011 | 30.93 | — |
| Lucas Buchanan | Option | 9,781 | 69.94 | — |
| Lucas Buchanan | Option | 7,500 | 55.3 | — |
| Lucas Buchanan | Option | 18,417 | 37.07 | — |
| Lucas Buchanan | Option | 15,070 | 37.07 | — |
| Andrew Davis | Option | 17,860 | 37.07 | — |
| Andrew Davis | Option | 2,011 | 30.93 | — |
| Andrew Davis | Option | 7,500 | 55.3 | — |
| Kevin Klemz | Option | 26,360 | 49.2 | — |
| Richard Ruedy | Option | 1,435 | 30.93 | — |
| Richard Ruedy | Option | 2,875 | 55.3 | — |
| Richard Ruedy | Option | 9,209 | 37.07 | — |
We have designed our executive compensation program to reward our executives at a level consistent with our overall strategic and financial performance and to provide remuneration sufficient to attract, retain, and motivate them. We believe that competitive compensation packages consisting of a combination of base salaries, annual bonus opportunities, and long-term incentive opportunities in the form of equity awards align the compensation of our executives with our performance and long-term value creation for our stockholders.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-06-18 | 24,560,759 | 5,253,533 | 1,263,145 | 82.38% | Passed |
| 2023 | 2023-06-21 | 13,904,626 | 20,247,589 | 25,367 | 40.71% | Failed |
| 2022 | 2022-06-09 | 26,863,568 | 4,646,835 | 48,976 | 85.25% | Passed |
| 2021 | 2021-06-17 | 26,610,564 | 4,364,672 | 12,324 | 85.91% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2024 | 2024-06-18 | 82.38%a |
| 2023 | 2023-06-21 | 40.71%b |
| 2022 | 2022-06-09 | 85.25%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 87 : 1 |
|---|---|
| CEO total compensation | — |
| Median employee compensation | $176,552 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Jack W. LasersohnIndependent · Board Chair · Audit · Nominating and Corporate Governance | $103,658 | $157,477 | $2,354 | — | $0 | $263,489 |
| Donald J. ZurbayIndependent · Audit (Chair) · Compensation | 70,658 | 157,477 | 0 | — | 0 | 228,135 |
| Rick D. AndersonIndependent · Compensation (Chair) · Nominating and Corporate Governance | 62,658 | 157,477 | 1,176 | — | 0 | 221,311 |
| Kevin J. BallingerIndependent · Audit · Compensation | 60,658 | 157,477 | 2,338 | — | 0 | 220,473 |
| Elizabeth H. WeathermanIndependent · Nominating and Corporate Governance (Chair) | 52,658 | 157,477 | 2,353 | — | 0 | 212,488 |
| Tanisha V. Carino, Ph.DIndependent · Nominating and Corporate Governance | 47,658 | 157,477 | 2,336 | — | 0 | 207,471 |
| Tony M. Chou, M.DIndependent · Audit · Compensation | 42,658 | 157,477 | 2,336 | — | 0 | 202,471 |
| Chas S. McKhannEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $157,500 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $440,606 |
| Equity awards (grant-date value) | $1,102,339 |
| All other compensation | $0 |
| Total cost of the board | $1,542,945 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Silk Road Medical names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Silk Road Medical.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Silk Road Medical | 2023 | Chas McKhann | $105,871 | $13,123,059 | $0 | $93,275 | $13,423,834 |
| 2 | Glaukos Corporation | 2025 | Thomas Burns | 850,000 | 7,649,947 | 3,527,497 | 0 | 12,034,087 |
| 3 | Alphatec Holdings, Inc. | 2025 | Patrick Miles | 762,000 | 8,859,650 | 0 | 600,000 | 10,260,507 |
| 4 | AtriCure, Inc. | 2025 | Michael Carrel | 828,439 | 7,203,478 | 0 | 1,171,703 | 9,217,620 |
| 5 | Inari Medical, Inc. | 2023 | Andrew Hykes | 700,000 | 2,606,744 | 937,488 | 826,000 | 5,083,365 |
| 6 | Outset Medical, Inc. | 2025 | Leslie Trigg | 755,166 | 2,197,882 | 0 | 294,515 | 3,255,510 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Silk Road Medical | not disclosed | RSU 70 · PSU 30 | not disclosed | Compensia |
| Alphatec Holdings, Inc. | 157% | PSU 50 · RSU 50 | No | Compensia, Inc. |
| AtriCure, Inc. | 141% | PSU 70 · RSU 30 | No | Korn Ferry |
| Glaukos Corporation | 177.5% | PSU 50 | No | Frederic W. Cook & Co., Inc. |
| Inari Medical, Inc. | not disclosed | RSU 75 · Option 25 | not disclosed | FW Cook |
| Outset Medical, Inc. | 39% | PSU 50 · RSU 50 | Yes — Relative TSR compared to Russell 2000 Medical Device Index | Pearl Meyer |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Chas McKhann | DEF 14A | 2024-04-26 | 0001397702-24-000024 | Section “Executive Compensation”. As printed: 13,423,834. Filing ↗machine: r2 · c8 · span 1756696–1756706 |
| 2 | Section 01, Erica Rogers | DEF 14A | 2024-04-26 | 0001397702-24-000024 | Section “Executive Compensation”. As printed: 8,159,904. Filing ↗machine: r4 · c8 · span 1766669–1766678 |
| 3 | Section 01, Lucas Buchanan | DEF 14A | 2024-04-26 | 0001397702-24-000024 | Section “Executive Compensation”. As printed: 6,624,943. Filing ↗machine: r7 · c8 · span 1782333–1782342 |
| 4 | Section 01, Andrew Davis | DEF 14A | 2024-04-26 | 0001397702-24-000024 | Section “Executive Compensation”. As printed: 4,866,640. Filing ↗machine: r10 · c8 · span 1798173–1798182 |
| 5 | Section 01, Kevin Klemz | DEF 14A | 2024-04-26 | 0001397702-24-000024 | Section “Executive Compensation”. As printed: 3,635,635. Filing ↗machine: r13 · c8 · span 1813380–1813389 |
| 6 | Section 01, Richard Ruedy | DEF 14A | 2024-04-26 | 0001397702-24-000024 | Section “Executive Compensation”. As printed: 1,965,300. Filing ↗machine: r16 · c8 · span 1829226–1829235 |
| 7 | Section 03, Chas McKhann PSU | DEF 14A | 2024-04-26 | 0001397702-24-000024 | Section “GRANTS OF PLAN-BASED AWARDS DURING 2023” · grants of plan-based awards table. Filing ↗machine: t92 · r4 · c9 · span 1939091–1939100 |
| 8 | Section 03, Lucas Buchanan PSU | DEF 14A | 2024-04-26 | 0001397702-24-000024 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t92 · r8 · c9 · span 1967094–1967101 |
| 9 | Section 03, Andrew Davis PSU | DEF 14A | 2024-04-26 | 0001397702-24-000024 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t92 · r12 · c9 · span 1992251–1992258 |
| 10 | Section 03, Andrew Davis RSU | DEF 14A | 2024-04-26 | 0001397702-24-000024 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t82 · r5 · c1 · span 1615626–1615633 |
| 11 | Section 03, Lucas Buchanan RSU | DEF 14A | 2024-04-26 | 0001397702-24-000024 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t92 · r9 · c9 · span 1972459–1972468 |
| 12 | Section 03, Lucas Buchanan RSU | DEF 14A | 2024-04-26 | 0001397702-24-000024 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t92 · r10 · c9 · span 1978002–1978011 |
| 13 | Section 03, Erica Rogers PSU | DEF 14A | 2024-04-26 | 0001397702-24-000024 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t92 · r6 · c9 · span 1953220–1953229 |
| 14 | Section 07, pay ratio | DEF 14A | 2023-04-28 | 0001397702-23-000025 | Section “CEO Pay Ratio”. As printed: 87 : 1. Filing ↗machine: span 534087–534089 |
| 15 | Section 08, Jack W. Lasersohn | DEF 14A | 2024-04-26 | 0001397702-24-000024 | Section “Director Compensation”. As printed: 263,489. Filing ↗ |
| 16 | Section 08, Donald J. Zurbay | DEF 14A | 2024-04-26 | 0001397702-24-000024 | Section “Director Compensation”. As printed: 228,135. Filing ↗ |
| 17 | Section 08, Rick D. Anderson | DEF 14A | 2024-04-26 | 0001397702-24-000024 | Section “Director Compensation”. As printed: 221,311. Filing ↗ |
| 18 | Section 08, Kevin J. Ballinger | DEF 14A | 2024-04-26 | 0001397702-24-000024 | Section “Director Compensation”. As printed: 220,473. Filing ↗ |
| 19 | Section 08, Elizabeth H. Weatherman | DEF 14A | 2024-04-26 | 0001397702-24-000024 | Section “Director Compensation”. As printed: 212,488. Filing ↗ |
| 20 | Section 08, Tanisha V. Carino, Ph.D | DEF 14A | 2024-04-26 | 0001397702-24-000024 | Section “Director Compensation”. As printed: 207,471. Filing ↗ |
| 21 | Section 08, Tony M. Chou, M.D | DEF 14A | 2024-04-26 | 0001397702-24-000024 | Section “Director Compensation”. As printed: 202,471. Filing ↗ |
| 22 | Section 08, Chas S. McKhann | DEF 14A | 2024-04-26 | 0001397702-24-000024 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 23 | Section 06, 2024 vote | Form 8-K | 2024-06-20 | 0001397702-24-000040 | Item 5.07 · say-on-pay result. As reported: 82.38% (votes for as printed: 24,560,759). Filing ↗ |
| 24 | Section 06, 2023 vote | Form 8-K | 2023-06-23 | 0001397702-23-000046 | Item 5.07 · say-on-pay result. As reported: 40.71% (votes for as printed: 13,904,626). Filing ↗ |
| 25 | Section 06, 2022 vote | Form 8-K | 2022-06-10 | 0001397702-22-000037 | Item 5.07 · say-on-pay result. As reported: 85.25% (votes for as printed: 26,863,568). Filing ↗ |
| 26 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 27 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 28 | Section 09b board cost (computed) | Computed | — | computed | Cash 440,606 + equity 1,102,339 + all other 0 = 1,542,945, summed across the director compensation table rows.machine: formula: Σ = 1,542,945 |
| 29 | Silk Road Medical (subject), Section 10b CEO total | DEF 14A | 2024-04-26 | 0001397702-24-000024 | CEO total compensation as printed in Silk Road Medical's own proxy. As printed: 13,423,834. Filing ↗machine: r2 · c8 · span 1756696–1756706 |
| 30 | Glaukos Corporation, Section 10b CEO total | DEF 14A | 2026-04-16 | 0001193125-26-157829 | CEO total compensation as printed in Glaukos Corporation's own proxy. As printed: 12,034,087. Filing ↗machine: t93 · r6 · c38 · span 1876942–1876952 |
| 31 | Alphatec Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191867 | CEO total compensation as printed in Alphatec Holdings, Inc.'s own proxy. As printed: 10,260,507. Filing ↗machine: t26 · r2 · c25 · span 858148–858158 |
| 32 | AtriCure, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001323885-26-000010 | CEO total compensation as printed in AtriCure, Inc.'s own proxy. As printed: 9,217,620. Filing ↗machine: span 743364–743373 |
| 33 | Inari Medical, Inc., Section 10b CEO total | DEF 14A | 2024-03-13 | 0001193125-24-066805 | CEO total compensation as printed in Inari Medical, Inc.'s own proxy. As printed: 5,083,365. Filing ↗machine: r2 · c31 · span 454508–454517 |
| 34 | Outset Medical, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177150 | CEO total compensation as printed in Outset Medical, Inc.'s own proxy. As printed: 3,255,510. Filing ↗machine: r2 · c30 · span 1343364–1343373 |
| 35 | Section 10a, AtriCure, Inc. reciprocity | DEF 14A | — | 0001323885-26-000010 | AtriCure, Inc.'s most recent proxy was read; its disclosed peer group does not include Silk Road Medical. Filing ↗ |
| 36 | Section 10a, Inari Medical, Inc. reciprocity | DEF 14A | — | 0001193125-24-066805 | Inari Medical, Inc. names Silk Road Medical in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 37 | Section 10a, Alphatec Holdings, Inc. reciprocity | DEF 14A | — | 0001193125-26-191867 | Alphatec Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Silk Road Medical. Filing ↗ |
| 38 | Section 10a, Glaukos Corporation reciprocity | DEF 14A | — | 0001193125-26-157829 | Glaukos Corporation's most recent proxy was read; its disclosed peer group does not include Silk Road Medical. Filing ↗ |
| 39 | Section 10a, Outset Medical, Inc. reciprocity | DEF 14A | — | 0001193125-26-177150 | Outset Medical, Inc.'s most recent proxy was read; its disclosed peer group does not include Silk Road Medical. Filing ↗ |